Atirmociclib - Pfizer
Alternative Names: PF-07220060Latest Information Update: 28 Oct 2025
At a glance
- Originator Pfizer
- Class Amines; Antineoplastics; Benzimidazoles; Cyclic ethers; Halogenated hydrocarbons; Propanols; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- Phase II Breast cancer; Solid tumours
- Phase I Prostate cancer
Most Recent Events
- 28 Oct 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA
- 08 Oct 2025 Pfizer plans a phase I pharmacokinetic trial in healthy volunteers in USA, in October 2025 (PO, Tablet) (NCT07215078)
- 09 Sep 2025 Pfizer plans a phase I pharmacokinetic trial in healthy volunteers (PO) (NCT07160738)